NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
